NO20051788L - Hydantoinderivater og deres anvendelse som TACE-inhibitorer - Google Patents
Hydantoinderivater og deres anvendelse som TACE-inhibitorerInfo
- Publication number
- NO20051788L NO20051788L NO20051788A NO20051788A NO20051788L NO 20051788 L NO20051788 L NO 20051788L NO 20051788 A NO20051788 A NO 20051788A NO 20051788 A NO20051788 A NO 20051788A NO 20051788 L NO20051788 L NO 20051788L
- Authority
- NO
- Norway
- Prior art keywords
- hydantoin derivatives
- tace inhibitors
- tace
- formula
- inhibitors
- Prior art date
Links
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 title abstract 2
- 150000001469 hydantoins Chemical class 0.000 title abstract 2
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108091007505 ADAM17 Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0221246.2A GB0221246D0 (en) | 2002-09-13 | 2002-09-13 | Compounds |
| PCT/GB2003/003914 WO2004024721A1 (en) | 2002-09-13 | 2003-09-09 | Hydantoin derivatives und deren verwendung als tace inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051788L true NO20051788L (no) | 2005-06-13 |
Family
ID=9943999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051788A NO20051788L (no) | 2002-09-13 | 2005-04-12 | Hydantoinderivater og deres anvendelse som TACE-inhibitorer |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060063818A1 (is) |
| EP (2) | EP1551826A1 (is) |
| JP (2) | JP2006507248A (is) |
| KR (1) | KR20050042499A (is) |
| CN (1) | CN1681804A (is) |
| AR (2) | AR043049A1 (is) |
| AU (2) | AU2003263347A1 (is) |
| BR (1) | BR0314275A (is) |
| CA (1) | CA2497571A1 (is) |
| GB (1) | GB0221246D0 (is) |
| IS (1) | IS7792A (is) |
| MX (1) | MXPA05002602A (is) |
| NO (1) | NO20051788L (is) |
| PL (1) | PL375877A1 (is) |
| RU (1) | RU2005106353A (is) |
| TW (2) | TW200406398A (is) |
| UY (1) | UY27972A1 (is) |
| WO (2) | WO2004024715A1 (is) |
| ZA (1) | ZA200501677B (is) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| WO2005000309A2 (en) * | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| AU2005252178B2 (en) * | 2004-06-02 | 2011-04-21 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| SE0401763D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
| US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| ATE478864T1 (de) | 2004-07-16 | 2010-09-15 | Schering Corp | Hydantoinderivate zur behandlung von entzündlichen erkrankungen |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| AR059036A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| TW200740769A (en) | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
| ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
| KR20080031487A (ko) * | 2006-06-28 | 2008-04-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴의 결정형 |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| AU2009271302A1 (en) * | 2008-06-24 | 2010-01-21 | Valeant Pharmaceuticals International | Benzyloxy anilide derivatives useful as potassium channel modulators |
| TW201024304A (en) | 2008-09-24 | 2010-07-01 | Schering Corp | Compounds for the treatment of inflammatory disorders |
| EP2346857B1 (en) | 2008-09-24 | 2019-11-27 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| EP2356111A1 (en) | 2008-11-10 | 2011-08-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US8569336B2 (en) | 2008-11-10 | 2013-10-29 | Ling Tong | Compounds for the treatment of inflammatory disorders |
| PT2789607T (pt) * | 2011-12-09 | 2018-03-22 | Kaken Pharma Co Ltd | Derivado de piridona e medicamento contendo o mesmo |
| EP2941423B1 (en) | 2013-01-07 | 2021-06-09 | University of Southern California | Deoxyuridine triphosphatase inhibitors |
| CN105531270B (zh) | 2013-06-07 | 2017-09-05 | 科研制药株式会社 | (+)－5－(3，4－二氟苯基)－5－[(3－甲基－2－氧吡啶－1(2h)－基)甲基]咪唑烷－2，4－二酮及含有该化合物的药物 |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| SI3319939T1 (sl) | 2015-07-08 | 2025-04-30 | Cv6 Therapeutics (Ni) Limited | Zaviralci deoksiuridin trifosfataze, ki vsebujejo hidantoin |
| WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| WO2018098204A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| WO2018128720A1 (en) | 2017-01-05 | 2018-07-12 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| CA3158234A1 (en) * | 2019-11-14 | 2021-05-20 | Foresee Pharmaceuticals Co., Ltd. | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2745875A (en) * | 1953-06-30 | 1956-05-15 | Hoechst Ag | Preparation of nu-acylamino-phenylpropane diols |
| US3452040A (en) * | 1966-01-05 | 1969-06-24 | American Home Prod | 5,5-disubstituted hydantoins |
| US3529019A (en) * | 1968-04-23 | 1970-09-15 | Colgate Palmolive Co | Alkylaryloxy alanines |
| US3849574A (en) * | 1971-05-24 | 1974-11-19 | Colgate Palmolive Co | Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate |
| US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
| GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
| JPS61212292A (ja) * | 1985-03-19 | 1986-09-20 | Mitsui Toatsu Chem Inc | Ｄ−α−アミノ酸の製造方法 |
| PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| WO1997019075A1 (en) * | 1995-11-22 | 1997-05-29 | Darwin Discovery Limited | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf) |
| GB9616643D0 (en) * | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
| US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| ATE212619T1 (de) * | 1996-10-22 | 2002-02-15 | Upjohn Co | Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren |
| IL132170A0 (en) * | 1997-05-06 | 2001-03-19 | Novo Nordisk As | Novel heterocyclic compounds |
| DE59802394D1 (de) * | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
| RU2208609C2 (ru) * | 1998-02-04 | 2003-07-20 | Новартис Аг | Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы |
| US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| EP1077974A1 (en) * | 1998-05-14 | 2001-02-28 | Du Pont Pharmaceuticals Company | Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| AU4692399A (en) * | 1998-06-17 | 2000-01-05 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| DK1004578T3 (da) * | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
| US6340691B1 (en) * | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| KR20020060160A (ko) * | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
| US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US20020091107A1 (en) * | 2000-09-08 | 2002-07-11 | Madar David J. | Oxazolidinone antibacterial agents |
| DE10047073C1 (de) * | 2000-09-22 | 2002-01-24 | Dbt Gmbh | Hydraulisch schaltbares Wegeventil |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| JP2004527511A (ja) * | 2001-03-15 | 2004-09-09 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼ阻害剤 |
| US6890915B2 (en) * | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| TWI220073B (en) * | 2003-07-24 | 2004-08-01 | Au Optronics Corp | Method for manufacturing polysilicon film |
-
2002
- 2002-09-13 GB GBGB0221246.2A patent/GB0221246D0/en not_active Ceased
-
2003
- 2003-09-05 TW TW092124646A patent/TW200406398A/zh unknown
- 2003-09-05 TW TW092124627A patent/TW200409769A/zh unknown
- 2003-09-09 MX MXPA05002602A patent/MXPA05002602A/es not_active Application Discontinuation
- 2003-09-09 PL PL03375877A patent/PL375877A1/xx not_active Application Discontinuation
- 2003-09-09 WO PCT/GB2003/003907 patent/WO2004024715A1/en not_active Ceased
- 2003-09-09 CN CNA038219557A patent/CN1681804A/zh active Pending
- 2003-09-09 EP EP03795075A patent/EP1551826A1/en not_active Withdrawn
- 2003-09-09 AU AU2003263347A patent/AU2003263347A1/en not_active Abandoned
- 2003-09-09 RU RU2005106353/04A patent/RU2005106353A/ru not_active Application Discontinuation
- 2003-09-09 BR BR0314275-2A patent/BR0314275A/pt not_active Application Discontinuation
- 2003-09-09 JP JP2004535653A patent/JP2006507248A/ja active Pending
- 2003-09-09 WO PCT/GB2003/003914 patent/WO2004024721A1/en not_active Ceased
- 2003-09-09 KR KR1020057004211A patent/KR20050042499A/ko not_active Withdrawn
- 2003-09-09 JP JP2004535650A patent/JP2006503829A/ja active Pending
- 2003-09-09 AU AU2003263345A patent/AU2003263345A1/en not_active Abandoned
- 2003-09-09 US US10/527,215 patent/US20060063818A1/en not_active Abandoned
- 2003-09-09 CA CA002497571A patent/CA2497571A1/en not_active Abandoned
- 2003-09-09 US US10/527,349 patent/US20050256176A1/en not_active Abandoned
- 2003-09-09 EP EP03795072A patent/EP1539740A1/en not_active Withdrawn
- 2003-09-11 UY UY27972A patent/UY27972A1/es not_active Application Discontinuation
- 2003-09-12 AR ARP030103319A patent/AR043049A1/es unknown
- 2003-09-12 AR ARP030103317A patent/AR041250A1/es unknown
-
2005
- 2005-02-25 ZA ZA200501677A patent/ZA200501677B/xx unknown
- 2005-04-11 IS IS7792A patent/IS7792A/is unknown
- 2005-04-12 NO NO20051788A patent/NO20051788L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004024721A1 (en) | 2004-03-25 |
| UY27972A1 (es) | 2004-04-30 |
| TW200406398A (en) | 2004-05-01 |
| GB0221246D0 (en) | 2002-10-23 |
| US20060063818A1 (en) | 2006-03-23 |
| ZA200501677B (en) | 2005-09-12 |
| CA2497571A1 (en) | 2004-03-25 |
| AR041250A1 (es) | 2005-05-11 |
| PL375877A1 (en) | 2005-12-12 |
| EP1551826A1 (en) | 2005-07-13 |
| KR20050042499A (ko) | 2005-05-09 |
| EP1539740A1 (en) | 2005-06-15 |
| BR0314275A (pt) | 2005-08-09 |
| JP2006503829A (ja) | 2006-02-02 |
| US20050256176A1 (en) | 2005-11-17 |
| AU2003263347A1 (en) | 2004-04-30 |
| MXPA05002602A (es) | 2005-05-05 |
| JP2006507248A (ja) | 2006-03-02 |
| AU2003263345A1 (en) | 2004-04-30 |
| WO2004024715A1 (en) | 2004-03-25 |
| RU2005106353A (ru) | 2005-10-10 |
| IS7792A (is) | 2005-04-11 |
| CN1681804A (zh) | 2005-10-12 |
| AR043049A1 (es) | 2005-07-13 |
| TW200409769A (en) | 2004-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20051788L (no) | Hydantoinderivater og deres anvendelse som TACE-inhibitorer | |
| AU2003282920A8 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| AU2003220401A8 (en) | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases | |
| WO2004032846A3 (en) | Triazolone and triazolethione derivatives | |
| AU2002357312A1 (en) | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases | |
| DE60234028D1 (de) | Hydantion-derivate als hemmer von matrix-metalloproteinasen | |
| NO971537D0 (no) | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser | |
| NO20051600L (no) | 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer | |
| NO20071320L (no) | Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer. | |
| NO20050199L (no) | Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet | |
| NO20005261L (no) | Nye heterocyklisk substituerte amider med cystein-protease- inhiberende virkning | |
| BR0111451A (pt) | Inibidores de serina protease | |
| NO20061157L (no) | 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer | |
| NO20060168L (no) | Pyridinylkarbamater som hormonsensitive lipaseinhibitorer | |
| NO20071242L (no) | Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer | |
| ATE228998T1 (de) | N-hydroxyformamid-derivate als inhibitoren von metalloproteinasen | |
| WO2003016248A3 (en) | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) | |
| WO2004012663A3 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme | |
| WO2004108086A3 (en) | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE) | |
| NO20012914D0 (no) | Nye amidinoderivater og deres anvendelse som trombininhibitorer | |
| ATE443044T1 (de) | Tace inhibitoren | |
| AU2003301903A8 (en) | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme | |
| DE602004018811D1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| NO20015892L (no) | Inhibitorer av metallproteinaser | |
| NO20023951L (no) | Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler |